Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
John B Bode is Director at Zevra Therapeutics. OQRO lists 3 transactions filed with the SEC under this name, the latest on Feb 4, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
2
2 buys, median +1.3 pts vs S&P 500, beat it 1 of 2 times.
Average +1.3 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Mar 21, 2025 to Aug 20, 2025, measured from the first close after the filing. Past results, not a forecast.
2 purchases disclosed; 50% of the 2 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.0 pts (median, against the S&P 500).
Jan 30, 202619Kdisclosed Feb 4
DetailsOfficial recordZevra TherapeuticsZVRA
2 disclosures · Mar 2025 – Aug 2025 · 2 bought
As of the latest filing on , John B Bode reported holding 45,000 shares of Zevra Therapeutics (ZVRA), worth about $423K at the last close of $9 (Nov 17, 2026). Holdings are also on file at Newton Golf Company (NWTG); together they are worth about $436K.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Zevra Therapeutics ZVRA | 45,000 | 45K direct | $9 | $423K | Aug 19, 2025 |
| Newton Golf Company NWTG | 18,549 | 19K direct | $1 | $13K | Jan 30, 2026 |
A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with .
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Aug 19, 2025Bought~$46Kdisclosed Aug 20
DetailsOfficial recordMar 19, 2025Bought~$80Kdisclosed Mar 21
DetailsOfficial recordJohn B Bode bought shares on the open market in 2023, 2024 and 2025.
John B Bode reported 10 open-market purchases and 0 sales since 2023; purchases in 3 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $125K2×2 trades | — |
| 2024 | $59K1×1 trade | — |
| 2023 | $102K7×7 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
John B Bode reported 10 open-market purchases and 0 sales here, 2023 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Aug 19, 2025, John B Bode reported holding 45,000 shares of Zevra Therapeutics (ZVRA). At the last close of $9 on Nov 17, 2026, that is about $423K. This is the stake disclosed in filings, not a net worth.
John B Bode bought shares on the open market in 2023, 2024 and 2025.
In SEC filings since 2023: the latest open-market purchase is from 2025; no open-market sale is on record.
Zevra Therapeutics (ZVRA), from 2023 to 2025: 10 purchases and 0 sales.